Home Private Equity International lab purchase backed by private equity

International lab purchase backed by private equity


UK-based medical device and pharmaceuticals testing group, Cormica, has completed the seven-figure purchase of TPM Laboratories (TPM) in New Jersey. Cormica, with funds from mid-market private equity company Limerston Capital. 

Cormica is focused on strategically expanding its capabilities across the US and Europe and TPM, an independent contract testing laboratory, delivers analytical services to the pharmaceutical and chemical industries, including analytical research and development, quality control and stability storage and testing services. 

Founded by Rupa Iyer in 2001, TPM operates from a state-of-the-art facility, spanning 8,000 square feet of office and laboratory space with capability to handle anti-cancer products.

As part of the acquisition, Rupa Iyer will continue to lead her team in the US with wider support from Cormica to develop the business. The deal will allow TPM to harness Cormica’s expertise and broad service line allowing it to grow organicall and reach its full potential. 

Cormica (formerly known as WMP Group) is a medical device, combination product and pharmaceutical testing group enabling life science manufacturers and innovators to launch their products more quickly, more safely and to more markets.

Mark Hammond, Cormica Group CEO, said: “The acquisition marks a milestone moment for Cormica and clearly demonstrates our ambitions to grow our international footprint and increase our market share in a highly competitive market.
“TPM boasts a highly skilled laboratory team with extensive pharmaceutical experience which has helped it to build a strong reputation for excellence. We are looking forward to working with Rupa and her team as we explore how we can help support the expansion of the business and use it to further our aims in the US, both organically and via further acquisitions.”

Rupa Iyer, President of TPM Laboratories, said: “I am proud of the success TPM has had to-date, but I also recognise that the business has the ability to scale-up. Cormica has a compelling offer, driven by people who understand the industry and how to create opportunities. This marks a new chapter in our story, and we are keen to work more closely with our colleagues in the UK and Europe.”

Jane Grewar, senior operating partner, Limerston Capital, added: “The first cornerstone of Cormica was established just over two years ago, with the acquisition of Wickham Micro, shortly followed by Medical Engineering Technologies and most recently a carve-out and integration of the analytical laboratory Cormica Bradford.”

Source link


Please enter your comment!
Please enter your name here